These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Grange F; Beylot-Barry M; Courville P; Maubec E; Bagot M; Vergier B; Souteyrand P; Machet L; Dalac S; Esteve E; Templier I; Delaporte E; Avril MF; Robert C; Dalle S; Laroche L; Delaunay M; Joly P; Wechsler J; Petrella T Arch Dermatol; 2007 Sep; 143(9):1144-50. PubMed ID: 17875875 [TBL] [Abstract][Full Text] [Related]
9. [Treatment of diffuse large B-cell lymphoma]. Gleissner B; Zwick C; Pfreundschuh M Dtsch Med Wochenschr; 2008 Sep; 133(36):1785-94; quiz 1795-6. PubMed ID: 18767006 [TBL] [Abstract][Full Text] [Related]
10. Patients with localized primary non-tonsillar oral diffuse large B-cell lymphoma exhibit favorable prognosis despite a non-germinal center B-cell-like phenotype. Sato Y; Onishi N; Morito T; Takata K; Mizobuchi K; Nagatsuka H; Ichimura K; Tanaka T; Tamura M; Yoshino T Cancer Sci; 2009 Jan; 100(1):42-6. PubMed ID: 19018759 [TBL] [Abstract][Full Text] [Related]
11. Primary diffuse large B-cell lymphoma of the stomach. Ferreri AJ; Montalbán C Crit Rev Oncol Hematol; 2007 Jul; 63(1):65-71. PubMed ID: 17339119 [TBL] [Abstract][Full Text] [Related]
12. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121 [TBL] [Abstract][Full Text] [Related]
13. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Navarro JT; Lloveras N; Ribera JM; Oriol A; Mate JL; Feliu E Haematologica; 2005 May; 90(5):704-6. PubMed ID: 15921395 [TBL] [Abstract][Full Text] [Related]
14. Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma. Morito T; Fujihara M; Asaoku H; Tari A; Sato Y; Ichimura K; Tanaka T; Takata K; Tamura M; Yoshino T Cancer Sci; 2009 Jul; 100(7):1255-60. PubMed ID: 19432905 [TBL] [Abstract][Full Text] [Related]
15. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement. Lee KW; Yi J; Choi IS; Kim JH; Bang SM; Kim DW; Im SA; Kim TY; Yoon SS; Lee JS; Bang YJ; Park S; Kim BK; Cho HI; Heo DS Ann Hematol; 2009 Sep; 88(9):829-38. PubMed ID: 19172274 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of primary mediastinal large B-cell lymphomas]. Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753 [TBL] [Abstract][Full Text] [Related]
17. Rituximab in diffuse large B-cell lymphoma. Coiffier B Clin Adv Hematol Oncol; 2004 Mar; 2(3):156-7. PubMed ID: 16166943 [No Abstract] [Full Text] [Related]
18. Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas. Guglielmi C; Martelli M; Federico M; Zinzani PL; Vitolo U; Bellesi G; Santini G; Tarella C; Zallio F; Pregno P; Di Renzo N; Resegotti L; Haematologica; 2001 Sep; 86(9):941-50. PubMed ID: 11532622 [TBL] [Abstract][Full Text] [Related]
19. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E; Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385 [TBL] [Abstract][Full Text] [Related]